EGFR and neoplasm: In a xenograft mouse model, the combination of EGFR and PI3K inhibitors reduced downstream signaling in the EGFR and PI3K pathways and inhibited the tumor growth in a statistically significant manner when compared to vehicle control (Fig. 6).